Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115123) titled 'A Trial of a PCSK9 Inhibitor in Advanced Breast Cancer' on Dec. 23, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University
Condition:
Breast cancer
Intervention:
Intervention Group:PCSK9 inhibitor 600mg Q3W ih
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2025-12-31
Target Sample Size: Intervention Group:30;Control Group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=302021
Published by HT Digital Content Services with permission from ...